Mind Medicine MindMed Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
DFTX$34.64-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders' Equity
(In thousands, except share amounts)
| Common Shares | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Additional Paid-In Capital | Accumulated OCI | Accumulated Deficit | Total | |
| Balance, December 31, 2023 | 41,101,303 | $— | $367,991 | $343 | $(290,200) | $78,134 |
| Issuance of common shares and warrants, net of share issuance costs | 38,624,064 | — | 234,267 | — | — | 234,267 |
| Issuance of common shares upon settlement of restricted share unit awards, net of shares withheld for tax | 650,801 | — | (54) | — | — | (54) |
| Exercise of 2022 USD Financing Warrants | 1,042,523 | — | 9,675 | — | — | 9,675 |
| Stock-based compensation expense | — | — | 12,960 | — | — | 12,960 |
| Exercise of stock options, net of options withheld for tax | 171,800 | — | 671 | — | — | 671 |
| Net loss and comprehensive loss | — | — | — | 478 | (73,938) | (73,460) |
| Balance, September 30, 2024 | 81,590,491 | $— | $625,510 | $821 | $(364,138) | $262,193 |
| Balance, December 31, 2022 | 37,979,136 | $— | $344,758 | $627 | $(194,468) | $150,917 |
| Issuance of common shares, net of share issuance costs | 1,402,598 | — | 4,943 | — | — | 4,943 |
| Exercise of 2022 USD Financing Warrants | 27,000 | — | 178 | — | — | 178 |
| Exercise of stock options | 13,333 | — | 49 | — | — | 49 |
| Settlement of restricted share unit awards | 672,641 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 11,610 | — | — | 11,610 |
| Net loss and comprehensive loss | — | — | — | 150 | (71,868) | (71,718) |
| Balance, September 30, 2023 | 40,094,708 | $— | $361,538 | $777 | $(266,336) | $95,979 |
| Common Shares | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Additional Paid-In Capital | Accumulated OCI | Accumulated Deficit | Total | |
| Balance, June 30, 2024 | 72,075,076 | $— | $551,668 | $833 | $(350,454) | $202,047 |
| Issuance of common shares and warrants, net of share issuance costs | 9,285,511 | — | 69,969 | — | — | 69,969 |
| Issuance of common shares upon settlement of restricted share unit awards, net of shares withheld for tax | 205,999 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 3,841 | — | — | 3,841 |
| Exercise of stock options, net of options withheld for tax | 23,905 | — | 32 | — | — | 32 |
| Net loss and comprehensive loss | — | — | — | (12) | (13,684) | (13,696) |
| Balance, September 30, 2024 | 81,590,491 | — | 625,510 | 821 | (364,138) | 262,193 |
| Balance, June 30, 2023 | 38,807,159 | $— | $354,023 | $362 | $(248,413) | $105,972 |
| Issuance of common shares, net of share issuance costs | 800,700 | — | 3,086 | — | — | 3,086 |
| Settlement of restricted share unit awards | 446,516 | — | — | — | — | — |
| Exercise of 2022 USD Financing Warrants | 27,000 | — | 178 | — | — | 178 |
| Exercise of stock options | 13,333 | — | 49 | — | — | 49 |
| Stock-based compensation expense | — | — | 4,202 | — | — | 4,202 |
| Net loss and comprehensive loss | — | — | — | 415 | (17,923) | (17,508) |
| Balance, September 30, 2023 | 40,094,708 | $— | $361,538 | $777 | $(266,336) | $95,979 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.